Durvalumab’s Benefit in SCLC ”Beyond What We Might Have Expected”
Oncology News Central Peer-Spectives
June 17, 202410m 29s
Audio is streamed directly from the publisher (mcdn.podbean.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
From ASCO 2024, Dr. Robert Figlin talks with Dr. Lauren Averett Byers from MD Anderson Cancer Center.
Durvalumab's Benefit in SCLC "Beyond What We Might Have Expected"